Matteo Lambertini, Marcello Ceppi, Francesca Poggio, Fedro A. Peccatori, Hatem A. Azim Jr., Donatella Ugolini, Paolo Pronzato, Sibylle Loibl, Halle C. F. Moore, Ann H. Partridge, Paolo Bruzzi, Lucia Del Mastro Ovarian suppression using luteinizing hormone- releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients. A meta-analysis of randomized studies Press Conference, ECC2015 (abstract: 1957) September 27 th, 2015 Vienna, Austria

Presented at the Press Conference, ECC2015 Presented by: Matteo Lambertini, MD Study Background (1/2) Approximately 11% of breast cancer occur in women younger than 45 years (25,500 in the US every year) with 6% in women under 40. Up to 97% will receive chemotherapy and are at risk for premature ovarian failure and infertility. Nearly 50% of young cancer survivors desire a pregnancy. Available options for fertility preservation: cryopreservation of embryos or oocytes, cryopreservation of ovarian tissue and temporary ovarian suppression with luteinizing hormone- releasing hormone (LHRHa) during chemotherapy.

Presented at the Press Conference, ECC2015 Presented by: Matteo Lambertini, MD Study Background (2/2) Cryopreservation of embryos or oocytes are standard strategies; 2-week delay to start anticancer therapies, surgical procedure and no ovarian function preservation. Temporary ovarian suppression with LHRHa during chemotherapy: no delay, widely availability, preservation of both ovarian function and fertility. The 2013 ASCO and ESMO guidelines still consider the use of LHRHa as an experimental strategy. The available randomized studies on LHRHa reported conflicting results; there is paucity of data available on long-term outcomes (pregnancies and survival events).

Presented at the Press Conference, ECC2015 Presented by: Matteo Lambertini, MD Results (1/2)

Presented at the Press Conference, ECC2015 Presented by: Matteo Lambertini, MD Results (2/2)

Presented at the Press Conference, ECC2015 Presented by: Matteo Lambertini, MD Conclusions Temporary ovarian suppression with LHRHa in young breast cancer patients is associated with a reduced risk of chemotherapy-induced premature ovarian failure and seems to increase the pregnancy rate, without apparent negative consequence on prognosis. The use of LHRHa during chemotherapy might be considered as an option for women interested in preserving their ovarian function, and might also play a role in increasing the likelihood of becoming pregnant after cessation of chemotherapy